Senseonics Holdings Inc. (SENS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Senseonics Holdings Inc. (SENS) surged +4.39% to $9.75, trading at 85% of its 52-week range ($4.79 – $10.64). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Claritev Corporation (CTEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TD Cowen analyst Joshua Jennings reiterates Senseonics Holdings (NASDAQ:SENS) with a Buy and maintains $15 price target.
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind Ever
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028Built on the proven sensing technology behind
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitori
Sensirion Holding has delivered a 44.4% return over the past year, which naturally raises a tougher question for you as an investor. Is the current share price at CHF 86.20 still in line with the cash flows the business
GERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitorin
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +56.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SENS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SENS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Senseonics Holdings Inc. (SENS) ranks #707 by composite RQD confidence (38/100, grade D-) and #444 by equity capitalization ($515.5M). Within this direct 5-issuer industry benchmark cohort, SENS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with SENS at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SENS
ACTIVE
Senseonics Holdings Inc. | D- | 38/100 | — | 44.7% | -35.0% | +4.39% | $515.5M | Benchmark Subject |
| RCEL Avita Medical Inc. | D | 44/100 | — | 82.1% | -35.0% | +1.27% | $516.8M | /rcel-vs-sens → |
| ANGO AngioDynamics Inc. | D | 50/100 | — | 54.6% | -23.4% | +1.81% | $519.4M | /ango-vs-sens → |
| DCTH Delcath Systems Inc. | D+ | 57/100 | — | 86.2% | 0.8% | -1.48% | $508.0M | /dcth-vs-sens → |
| SGHT Sight Sciences Inc. | D- | 38/100 | — | 86.2% | -35.0% | +3.57% | $527.2M | /sght-vs-sens → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Senseonics Holdings Inc. (SENS) reported GAAP revenue of $35.3M (+56.9% vs. FY2024 revenue of $22.5M , and +57.5% cumulative change since FY2023) , GAAP net income of -$69.1M, operating cash flow of -$59.1M, and free cash flow of -$59.1M (+2.2% YoY). On the balance sheet, SENS closed FY2025 with $126.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.3M | -$69.1M | -$59.1M | -$59.1M | $126.3M | — |
| FY2024 (FY) | 2024-12-31 | $22.5M | -$78.6M | -$60.5M | -$60.5M | $100.4M | — |
| FY2023 (FY) | 2023-12-31 | $22.4M | -$60.4M | -$70.2M | -$70.2M | — | — |
As of 2026-11-01, Senseonics Holdings Inc. (NASDAQ: SENS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.75 (+4.39% 1D, market cap $515.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SENS ranks #707 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SENS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 44.7%, and ROIC of -35.0%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and ANGO (AngioDynamics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -23.4%, cap $519.4M). Among the 5-stock peer group, SENS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
Per SENS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001616543), Senseonics Holdings Inc. generated $35.3M in revenue (+56.9% YoY), -$69.1M in net income, and -$59.1M in free cash flow against $126.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SENS last traded at $9.75 (+4.39% on volume of 522,711 shares), positioning the stock +6.09% above its 50-day simple moving average ($9.19) and +35.42% above its 200-day simple moving average ($7.20). Across its 52-week range of $4.79 to $10.64, SENS sits at the 84.8% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.53 to $10.97).
Why SENS Stock surged +4.39% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.